Aurobindo Pharma to acquire US-based Lannett for $250 million
Aurobindo Pharma, based in Hyderabad, is making a big move in the US by buying Lannett Company LLC for $250 million (about ₹2,185 crore).
The deal is all about boosting Aurobindo's manufacturing power and adding more high-value generic medicines to its lineup—especially in the US market.
Lannett's financials andIN and focus: Focus areas
Lannett isn't new to the game. Founded back in 1942 and based in Pennsylvania, they focus on complex generics like non-opioid controlled substances.
Their Indiana facility can pump out up to 3.6 billion tablets a year.
In 2024 alone, they made $286 million (₹2,499 crore), and they're expected to do even better in 2025.
Aurobindo to gain access to ADHD meds
With this buyout, Aurobindo gets access to Lannett's ADHD meds and a growing contract manufacturing business.
Plus, it gives them serious US-based production muscle.
In short: it's a smart step for Aurobindo to grow stronger in the competitive US generic drug scene.
```